Status:
COMPLETED
Lurasidone Non-Interventional Study in Schizophrenia Patients
Lead Sponsor:
Aziende Chimiche Riunite Angelini Francesco S.p.A
Collaborating Sponsors:
Hippocrates Research
Conditions:
Schizophrenia
Eligibility:
All Genders
18-99 years
Brief Summary
The study is a multicentric, national, non-interventional, prospective, single arm study. The main goal of this study is to gather information about the effects, in a real-life setting, of lurasidone...
Detailed Description
Important aim of the study is to investigate, aspects related to effectiveness, safety and tolerability at 3 months' lurasidone treatment in a routine practice in Italian clinical settings. Only pati...
Eligibility Criteria
Inclusion
- Adult (≥18 years) male or female subjects;
- Primary diagnosis of schizophrenia
- Patients not previously treated with lurasidone. The choice to initiate lurasidone treatment is independent of being included in the study;
- Patients legally capable of giving their written consent for participation in the study and for personal data processing.
Exclusion
- Concomitant participation in a clinical trial
Key Trial Info
Start Date :
October 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 12 2023
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT06527885
Start Date
October 21 2022
End Date
September 12 2023
Last Update
August 1 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST degli Spedali Civili di Brescia
Brescia, Italy
2
Villa Von Siebenthal
Genzano di Roma, Italy, 00045
3
Azienda Sanitaria Azienda ospedaliero-universitaria Senese
Siena, Italy, 53100